NEAR-FINAL AGENDA - National Cancer Institute



AGENDA

NCI-ASTRO WORKSHOP

ERADICATING METASTASES: EMERGING OPPORTUNITIES FOR RADIATION TO HELP CURE M1 DISEASE

Natcher Conference Center, National Institutes of Health.

Dec 5-6, 2007.

THERE IS NO FEE FOR ATTENDING THIS WORKSHOP BUT PRE-REGISTRATION IS NECESSARY AS SEATING IS LIMITED.

TO PRE-REGISTER PLEASE CONTACT:

Bhadrasain Vikram, MD

Chief - Clinical Radiation Oncology Branch,

RRP/DCTD

National Cancer Institute,

6130 Executive Blvd, Suite 6002,

Rockville MD 20852.

Tel: 301 496 6111

Fax: 301 480 5785

e-mail: vikramb@mail.

WEDNESDAY DEC. 5

7:45-8 AM. OPENING REMARKS.

STEREOTACTIC BODY RADIATION THERAPY AND HYPOFRACTIONATION FOR METASTASES

• 8-8:15 AM. Robert Timmerman (UT Southwestern): SBRT as a debulking or ablative treatment for metastatic cancer.

• 8:15-8:30 AM. Michael Milano (Univ of Rochester): Descriptive analysis of oligometastatic lesions treated with curative intent by stereotactic body radiation therapy.

• 8:30-8:45 AM. Brian Kavanagh (Univ of Colorado): SBRT for metastases: Dose-response analysis in 150 patients and Histopathology of Normal tissue changes in lung and liver

• 8:45-9 AM. Michael Zelefsky (Memorial Sloan-Kettering Cancer Center): Single Fraction High Dose radiation therapy for Bone and Soft Tissue metastases.

• 9-9:30 AM. Zvi Fuks (Memorial Sloan-Kettering Cancer Center): The Biological Basis of Single Dose Radiotherapy.

HETEROGENEITY AND IMAGING OF METASTASES

• 9:30-10 AM. Ralph Weichselbaum (Univ of Chicago): Predictive value of gene signatures in the context of treating oligometastases by irradiation.

10-10:30 AM. DISCUSSION

10:30-10:45 AM. BREAK

• 10:45-11:15 AM. Lalitha Shankar (NIH): Molecular and functional imaging for assessing the biology of metastases and its potential impact on patient management.

• 11:15-11:45 AM. Hedvig Hricak (Memorial Sloan-Kettering Cancer Center): MRI for depicting and characterizing the biology and heterogeneity of cancers: lessons learned from image-pathology correlation in recurrent cancers of the prostate.

• 11:45-12:15 PM. Rakesh Jain (Massachusetts General Hospital): Normalization of tumor vasculature and microenvironment: From the bench to bedside and back.

12:15-12:30 PM. DISCUSSION.

12:30-1:30 PM. LUNCH BREAK

• 1:30-2 PM. Richard Hill (Univ of Toronto): Cancer Stem Cells and the Radiation therapy of metastatic disease.

THE NEW IMRT: IMMUNITY-MODULATING RADIATION THERAPY

• 2-2:30 PM. Chandan Guha (Albert Einstein College of Medicine): Radiation-enhanced antigen presentation / A primer of Immunology for Radiation Oncologists

• 2:30-3 PM. James Gulley (NIH): Combining Immunotherapy with Radiotherapy: Rationale and initial clinical results of 2 clinical trials.

• 3-3:30 PM. Silvia Formenti (New York University): The irradiated tumor site as immunological hub.

3:30-4 PM. DISCUSSION.

4-4:15 PM. BREAK.

• 4:15-4:45 PM. George Schreiner (Raven Biotechnologies): Immunological implications of radiation conditioning

• 4:45-5:15 PM. Dennis Hallahan (Vanderbilt Univ): Stereotactic Irradiation Activates Immune Response in Cancer.

5:15-6 PM. DISCUSSION.

THURSDAY DEC. 6

OTHER NOVEL APPROACHES

• 8-8:30 AM. Luka Milas (MD Anderson Cancer Center): CpG oligodeoxynucleotides combined with radiotherapy for systemic anti-metastatic effect.

• 8:30-9 AM.Victor Frenkel (NIH): Focused ultrasound for enhancing through thermal and non-thermal mechanisms the effects of drugs and immunotherapy on cancers.

• 9-9:30 AM. Steven Rosenberg (NIH): Total body irradiation as a preparative regimen for the immunotherapy of metastatic cancer in humans.

• 9:30-10 AM. Susanta Hui (Univ of Minnesota): A novel technique for total bone marrow irradiation that may prove safer than TBI for lymphodepletion and adoptive immunotherapy.

• 10-10:30 AM. Bin Zhang (Univ of Chicago): Radiation-induced sensitization of the stroma leads to eradication of established cancer by T cells.

10:30-11 AM. DISCUSSION.

11-11:15 AM. BREAK

• 11:15-11:45 AM. Ralph Weichselbaum (Univ of Chicago): Genetically modified and ionizing radiation-activated viruses for controlling metastatic cancers.

SYSTEMIC TARGETED RADIONUCLIDE THERAPY

• 11:45-12:15 PM. Donald Buchsbaum (Univ of Alabama): Radiolabeled antibodies for the treatment of metastatic disease

• 12:15-12:45 PM. Roger Macklis (Cleveland Clinic): Biologically targeted radiopharmaceuticals for metastatic disease: Clinical aspects.

12:45-1 PM. DISCUSSION.

1-2 PM. LUNCH BREAK

• 2-2:30 PM. Martin Brechbiel (NIH): Preclinical studies of alpha radiation in conjunction with chemotherapeutic agents.

• 2:30-3 PM. Dennis Hallahan (Vanderbilt Univ) : Targeting radiation-inducible neoantigens with radioconjugated peptides.

• 3-3:30 PM. Mohamed Khan (Roswell Park Cancer Institute): Development of Composite Nanodevices for improved Imaging and Radiation Therapy of Metastases.

3:30-5 PM. ROUND-TABLE DISCUSSION AND CLOSING REMARKS.

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download